Arch Biopartners (TSXV:ARCH) Completes CAD 600k Placement to Advance Clinical Programs

Highlights

• Arch Biopartners has raised CAD 600,000 through a non-brokered private placement.
• The offering comprised 576,923 shares priced at CAD 1.04 each.
• Proceeds will be used for working capital and operating expenses not covered by trial grants.
• The company is advancing LSALT peptide and Cilastatin programs for AKI, alongside pre-clinical CKD therapies.

Arch Biopartners Inc. (TSX-V:ARCH) (OTCQB:ACHFF), a therapeutic biotechnology company, has successfully closed a non-brokered private placement. The company issued 576,923 common shares at $1.04 per share, raising gross proceeds of CAD 600,000. This final amount represents a CAD 100,000 increase from the previously disclosed figure on November 10, 2025.

The proceeds would support general working capital and certain operating expenses not covered by existing human trial funding grants. The completion of the offering remains subject to standard conditions, including final regulatory approval from the TSX Venture Exchange.

Advancing Kidney Disease Drug Development  

Arch Biopartners is focused on developing novel treatments for acute kidney injury (AKI) and chronic kidney disease (CKD). The company is advancing programs that target inflammation-related and toxin-related kidney injury through mechanism-based drug candidates.

Its pipeline includes the LSALT peptide, currently in a Phase II trial evaluating its potential to address cardiac surgery-associated AKI. The company is also developing Cilastatin, a repurposed drug in a Phase II trial for toxin-induced AKI. Additionally, Arch is pursuing pre-clinical CKD therapies targeting chronic forms of kidney disease.

These programs aim to address unmet clinical needs affecting more than 800 million patients globally.Read the latest updates on the LSALT peptide clinical trial.

Details of the Placement (Related Party Transaction)

The offering included the issuance of 480,923 common shares to a Company officer considered a “related party” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. As a result, the transaction qualifies as a related party transaction under MI 61-101.

The company stated that the offering is exempt from the formal valuation and minority shareholder approval requirements in sections 5.5(a) and 5.7(a) of MI 61-101. This exemption applies because the fair market value of the securities issued, as well as the consideration received from the related party, does not exceed 25% of Arch’s market capitalization.

No finders’ fees were paid, and all issued common shares are subject to a hold period of four months and one day from the closing date.

Shares of ARCH closed at CAD 1.05 on November 19, 2025.